Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
HBIO logo HBIO
Upturn stock ratingUpturn stock rating
HBIO logo

Harvard Bioscience Inc (HBIO)

Upturn stock ratingUpturn stock rating
$0.51
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/16/2025: HBIO (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

2 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $4.5

Year Target Price $4.5

Analyst’s Price TargetsFor last 52 week
$4.5Target price
Low$0.28
Current$0.51
high$3.6

Analysis of Past Performance

Type Stock
Historic Profit 64.28%
Avg. Invested days 40
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/16/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 20.50M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) -
Beta 1.55
52 Weeks Range 0.28 - 3.60
Updated Date 06/29/2025
52 Weeks Range 0.28 - 3.60
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.31

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -63.52%
Operating Margin (TTM) -7.46%

Management Effectiveness

Return on Assets (TTM) -2.38%
Return on Equity (TTM) -138.8%

Valuation

Trailing PE -
Forward PE 14.93
Enterprise Value 59558492
Price to Sales(TTM) 0.22
Enterprise Value 59558492
Price to Sales(TTM) 0.22
Enterprise Value to Revenue 0.65
Enterprise Value to EBITDA 179.26
Shares Outstanding 44213700
Shares Floating 33973842
Shares Outstanding 44213700
Shares Floating 33973842
Percent Insiders 8.27
Percent Institutions 69.66

Analyst Ratings

Rating 4
Target Price 4.5
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Harvard Bioscience Inc

stock logo

Company Overview

overview logo History and Background

Harvard Bioscience, Inc. (HBIO) was founded in 1901. Initially focused on kymographs and physiological recorders, it has evolved through acquisitions and internal development to offer a broader range of tools for life science research and clinical applications.

business area logo Core Business Areas

  • Cellular and Molecular Products: Includes electrophoresis equipment, imaging systems, and other tools for cell and molecular biology research.
  • Physiology Products: Offers instruments for measuring physiological parameters in animals and humans, such as ventilators, pumps, and data acquisition systems.
  • Data Acquisition & Analysis Software: Provides data analysis for Physiology and Cellular and Molecular research
  • Preclinical Solutions: Offerings for small animal in vivo studies (behavior, physiology, imaging etc.)

leadership logo Leadership and Structure

Harvard Bioscience is led by a CEO and a board of directors. The organizational structure is departmentalized, with divisions focusing on product development, sales and marketing, and operations.

Top Products and Market Share

overview logo Key Offerings

  • Harvard Apparatus Ventilators: Used for rodent and small animal ventilation in research. Market share is estimated to be between 20-25%. Competitors include Kent Scientific and Hugo Sachs Elektronik.
  • DSI telemetry implants: Wireless physiological monitoring technology for preclinical research. Revenue are significant, but public market share data are difficult to acquire. Competitors include Transoma Medical and emka TECHNOLOGIES.

Market Dynamics

industry overview logo Industry Overview

The life science tools market is driven by increasing R&D spending in pharmaceuticals, biotechnology, and academic research. Key trends include automation, miniaturization, and the integration of data analytics.

Positioning

Harvard Bioscience occupies a niche position in the market, focusing on specialized tools for specific applications. Their competitive advantage lies in their established brand and reputation for quality.

Total Addressable Market (TAM)

The TAM for life science tools is estimated at over $100 billion. Harvard Bioscience addresses a portion of this market with its specialized product offerings. Its TAM is likely in the range of $2-5B

Upturn SWOT Analysis

Strengths

  • Established brand reputation
  • Specialized product portfolio
  • Strong customer relationships in research institutions

Weaknesses

  • Smaller scale compared to larger competitors
  • Dependence on research funding cycles
  • Limited global presence

Opportunities

  • Expanding into emerging markets
  • Developing new products for personalized medicine
  • Acquiring complementary technologies

Threats

  • Increased competition from larger players
  • Changes in research funding priorities
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • Thermo Fisher Scientific (TMO)
  • Danaher Corporation (DHR)
  • Agilent Technologies (A)

Competitive Landscape

Harvard Bioscience faces intense competition from larger, more diversified companies. Their advantage lies in their specialized expertise and focus on niche markets. However the overall Market Share is less than 1% of TAM.

Major Acquisitions

Data Sciences International (DSI)

  • Year: 2005
  • Acquisition Price (USD millions): 93
  • Strategic Rationale: Expanded HBIO's portfolio into preclinical monitoring technologies.

Growth Trajectory and Initiatives

Historical Growth: Growth has been inconsistent, dependent on acquisitions and market conditions.

Future Projections: Analyst estimates vary. Future growth will likely depend on successful product development and market expansion.

Recent Initiatives: Check recent press releases and investor presentations for strategic initiatives.

Summary

Harvard Bioscience is a niche player in the life science tools market with a long history. Their specialization provides some advantage, but they face stiff competition from much larger companies. Financial performance has been inconsistent. Careful product development and expansion into high-growth markets are needed for long-term success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q), Investor Presentations, Press Releases, Market Research Reports, Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share estimates are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Harvard Bioscience Inc

Exchange NASDAQ
Headquaters Holliston, MA, United States
IPO Launch date 2000-12-07
President, CEO & Chairman Mr. James W. Green
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 330
Full time employees 330

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.